Pharmaceutical Sales Jobs
|
One-Stop Resume Posting to Over 75 Career Sites. Click Here |
|
|
Our list of pharmaceutical sales jobs consists of a page for each state, and each page combines the results from several job search engines. Our paradigm is similar to the meta-search engines like Dogpile, except here we combine the results from job search engines as opposed to regular search engines.
Here we also provide to the pharmaceutical sales representative informative articles, useful statistics, videos, a selection of books, and current pharmaceutical industry news. The pharmaceutical sales jobs listed here are in the form of RSS feeds, and will be automatically updated when new jobs become available. This site is produced by IntellegoJobs, a division of Intellego Web Publishing.
The following data should be interesting to the pharmaceutical sales rep who resides within the United States. This data comes from the Bureau of Labor Statistics.
Sales Representatives for Technical and Scientific Products - Statistics (Bureau of Labor Statistics)
States with the highest concentration of sales representatives for technical and scientific products with annual salary:
(highest at top)
New Hampshire $77,120
Massachusetts $88,550
Utah $74,800
South Dakota $63,310
Arizona $61,560
Top paying states for sales representatives for technical and scientific products with annual salary:
(highest at top)
Delaware $91,220
Massachusetts $88,550
Maryland $85,790
Minnesota $85,090
District of Columbia $85,050
Mean annual salary for sales representatives for technical and scientific products:
$76,460
Metropolitan areas with the highest concentration of sales representatives for technical and scientific products with annual salary:
Nashua, NH-MA NECTA Division $78,780
Framingham, MA NECTA Division $74,970
Lowell-Billerica-Chelmsford, MA-NH NECTA Division $99,010
San Jose-Sunnyvale-Santa Clara, CA $100,000
Lake County-Kenosha County, IL-WI Metropolitan Division $88,440
Top paying metropolitan areas for sales representatives for technical and scientific products:
Sacramento—Arden-Arcade—Roseville, CA $102,360
San Jose-Sunnyvale-Santa Clara, CA $100,000
Lowell-Billerica-Chelmsford, MA-NH NECTA Division $99,010
Bridgeport-Stamford-Norwalk, CT $98,520
Wenatchee, WA $98,100
Industries with the highest level of employment for the sales representatives for technical and scientific products:
(highest at top)
Professional and Commercial Equipment and Supplies Merchant Wholesalers
Wholesale Electronic Markets and Agents and Brokers
Drugs and Druggists’ Sundries Merchant Wholesalers
Electrical and Electronic Goods Merchant Wholesalers
Computer Systems Design and Related Services
Top paying industries for sales representatives for technical and scientific products
Satellite Telecommunications $107,050
Other Professional, Scientific, and Technical Services $102,100
Other Motor Vehicle Dealers $97,980
Other Telecommunications $92,770
Computer and Peripheral Equipment Manufacturing $91,080
Training and requirements needed for the sales representatives for technical and scientific products:
Today, more frequently then not, employers are hiring sales representatives with a college degree, regardless of the type of product you are selling. If you want to be a pharmaceutical sales representative, indeed you should have a college degree. As a matter of fact, in most cases, you need a college degree if you want to sell any technical or scientific product.
The usual characteristics of any successful salesman such as a friendly personality, the ability to sell, and familiarity with the brand are also looked for in the pharmaceutical sales representative. Also, more so then many other sales positions, you need to sell the product to the physician within a very short period of time, usually a matter of minutes. This is simply because most doctors do not not have the time to listen to a long sales pitch.
In the pharmaceutical industry, it is essential that the sales rep have a complete and thorough knowledge of the drug he or she is selling. This includes side effects, interactions, efficacy, clinical trial data and more. Therefore extensive knowledge from the disciplines of chemistry and human biology are essential, along with a thirst for learning and understanding. Knowledge about drugs and medicines is also picked up from seminars and on the job training.
For more information about training required for the pharmaceutical sales representative in the United States go to Occupational Outlook Handbook provided by the Bureau of Labor Statistics.
Pharmaceutical Sales Jobs - Employment Growth and Outlook
Overall, sales employment growth in the United States is expected to be about average. Employment growth is expected to be around 9% between 2006 and 2016, which is average relative to all other occupations. It should be noted that this is for all sales positions.
As the elderly population in the United States continues to grow in size, their need for various medicines will also continue to grow. Drug companies will need to produce medicines with a high level of efficacy and fewer side effects in order to meet the medical needs of an increasing elderly population. Because the pharmaceutical sales representative is the interfacing pipeline between the drug company and the physician, this type of sales representative should continue to see increasing employment opportunities. Therefore, employment growth for the pharmaceutical sales representative should be greater then that which is expected for other sales positions.
It should also be noted that competition for technical and scientific product sales positions will be keen, including pharmaceutical sales representatives. This is because of the higher salary offered to individuals who hold these positions.
Source for the above data:
E-Mail your Resume and Cover Letter to 1000’s of Headhunters, Click Here
Pharmaceutical Sales Jobs - Videos About the Resume
|
|
The following is a current listing of job openings in the United States for the pharmaceutical sales representative.
Pharmaceutical Sales Jobs - Listed by State - Updated Daily
Pharmaceutical Industry News
Pharma Industry / Biotech Industry News From Medical News Today
Copyright 2010 Medical News Today
Latest Health News and Medical News posted throughout the day, every day.
BIO Joins Stakeholders In Expressing Concerns With Efforts To Restrict Gene Patenting
The Biotechnology Industry Organization (BIO) released a letter to Health and Human Services Secretary Kathleen Sebelius regarding the potentially harmful recommendations of the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) in its Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests...
Gaining Market Access By Providing Value For Money
Cost-effectiveness research will become more important as EU responsibility for the pharmaceutical sector moves to the Health and Consumer policy directorate, Lynne Taylor and Peter Mansell report...
Frank Semcer Is First To Be Honored With Stevens' Award For Innovation And Entrepreneurship
At Micro Stamping headquarters in Somerset, New Jersey, it is largely what is not visible that gives the metal-forming company its edge in the highly competitive world of precision component manufacturing. Chairman Frank Semcer, Sr...
State Policy Developments: Iowa Seeks To Extend Birth Control Coverage; Minn. Eyes More Health Care For Poor; Miss. Drug Settlement
BusinessWeek: "Mississippi will receive $18.5 million from drug maker Eli Lilly and Co. as part of a settlement over claims the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat, Attorney General Jim Hood said Thursday" (Byrd, 2/4)...
First Measurement Of Energy Released From A Virus During Infection
Within a virus's tiny exterior is a store of energy waiting to be unleashed. When the virus encounters a host cell, this pent-up energy is released, propelling the viral DNA into the cell and turning it into a virus factory...
Health Bill Stall Creates Uncertainty For Drug Makers
"With the possible demise of health care legislation, getting back to business as usual may not be the best thing for the nation's drug makers," The New York Times reports...
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a significant unmet medical need...
QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM)...
CREON(R) (pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption In Children With Cystic Fibrosis
Solvay Pharmaceuticals, Inc...
Launch Of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22...
PharmAthene Submits White Paper To BARDA For Advanced Development Funding For SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
PharmAthene, Inc...
NovaBay Pharmaceuticals To Present At The 2010 BIO CEO & Investor Conference
NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biopharmaceutical company developing first-in-class, anti-infective compounds in the treatment and prevention of antibiotic-resistant infections, today announced that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the 12th Annual BIO CEO & Investor Conference on Tuesday, Feb...
BIO Proposes Second Wave Of Advanced Biofuel Commercialization Policy To Stimulate Job Creation
Additional Congressional action is needed to follow through on the Obama administration's recently announced initiative to rapidly build an integrated value chain for the bioeconomy, create jobs and kick start economic growth. The Biotechnology Industry Organization (BIO) today released proposed policy options that provide needed incentives to support U.S...
Judge Hears Arguments In Challenge To Patents On Genes Tied To Breast, Ovarian Cancer
U.S. District Judge Robert Sweet on Tuesday considered whether to invalidate Myriad Genetics' patents on two genes associated with an increased risk of breast and ovarian cancers in a lawsuit that could have far-reaching implications for the biotechnology industry and genetics-based research, the AP/ABC News reports...
Protalix Announces Presentation Of Phase III Taliglucerase Alfa Data At WORLD Lysosomal Disease Network
Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida. Hanna Rosenbaum, M.D...
Paloma Pharmaceuticals Receives Approval To Enter Phase I Clinical Trials
Paloma Pharmaceuticals, Inc. announced that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD)...
Access Pharmaceuticals Initiates Program Applying Cobalamin Platform To SiRNA Drug Delivery
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies...
Study Finds Nurse Educators Significantly Increase Awareness For Product Launch
Quintiles have announced findings from a recent study from a program in which a team of 19 nurse educators helped raise awareness of a newly approved oncology drug for a major pharmaceutical company from 37% to 57%...
Drug Company CEOs Under Pressure
News outlets feature profiles and opinions of the CEOs of some of the largest American drug manufacturers. Dow Jones Newswires/The Wall Street Journal on Severin Schwan, chief executive of Swiss pharmaceutical company Roche Holding AG: "'It is difficult to gauge the impact of the planned U.S...
Also In Global Health News: GSK's Interest In NTDs; Kenya's Male Circumcision Drive; Dengue Fever; HIV Prevention In Jamaica; Food Shortages In Zimbab
GSK Head Discusses Company Interest In NTDs The Associated Press features a Q&A with GlaxoSmithKline (GSK) CEO Andrew Witty, who "is pushing to sell more products in fast-growing 'emerging markets' such as Brazil, Russia, India and China" while simultaneously "increasing efforts to bring medicines for tropical diseases to the poorest countries, at minimum profit...
BIO Welcomes Obama Proposal To Achieve Advanced Biofuels Targets, Final Rules On Renewable Fuel Standard
The Obama administration's new biofuels initiative is a much-needed step in federal coordination that can help pioneer companies secure the investment needed to build large-scale advanced biofuels production facilities...
Court Weighs Patents For Human Genes
The American Civil Liberties Union has sued a genetics company that holds patents on breast- and ovarian-cancer-causing genes, saying their claims on the two genes hinders further research by other companies and scientists, the Associated Press/CBS News reports. ACLU lawyers have argued the discovery of the genes should not be rewarded with a patent because each is an "ancient secret of nature...
SOMA 250 MG Shown To Significantly Improve Functionality And Reduce Disability In Patients With Low Back Pain In Three Days
A recent analysis of two pivotal clinical trials in patients with acute low back pain (ALBP) who were treated with SOMA® (carisoprodol) 250 mg showed significantly improved functionality and reduced disability after three days of treatment, as measured by the Roland-Morris Disability Questionnaire (RMDQ)...
Keryx Biopharmaceuticals Announces Protocol Assessment Agreement With FDA For Phase 3 Trial Of KRX-0401 (Perifosine) To Treat Colorectal Cancer
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer...
Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial For Treatment Of Recurrent Venous Thromboembolism
Daiichi Sankyo Company, Limited (TSE: 4568), announced that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor...
7r5wk2sayt
Powered by FirstRSS Plugin
